Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer.
1997613 citationsMika A. Sovak, Robert E. Bellas et al.Journal of Clinical Investigationprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
Countries citing papers authored by G E Sonenshein
Since
Specialization
Citations
This map shows the geographic impact of G E Sonenshein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G E Sonenshein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G E Sonenshein more than expected).
This network shows the impact of papers produced by G E Sonenshein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G E Sonenshein. The network helps show where G E Sonenshein may publish in the future.
Co-authorship network of co-authors of G E Sonenshein
This figure shows the co-authorship network connecting the top 25 collaborators of G E Sonenshein.
A scholar is included among the top collaborators of G E Sonenshein based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with G E Sonenshein. G E Sonenshein is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Landesman‐Bollag, Esther, et al.. (2001). Roles of IKK kinases and protein kinase CK2 in activation of nuclear factor-kappaB in breast cancer.. PubMed. 61(9). 3810–8.137 indexed citations
Sovak, Mika A., et al.. (1999). The inhibitory effects of transforming growth factor beta1 on breast cancer cell proliferation are mediated through regulation of aberrant nuclear factor-kappaB/Rel expression.. PubMed. 10(8). 537–44.82 indexed citations
Sovak, Mika A., Robert E. Bellas, Dong Wook Kim, et al.. (1997). Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer.. Journal of Clinical Investigation. 100(12). 2952–2960.613 indexed citations breakdown →
7.
Arsura, Marcello, Mark J. Fitzgerald, N Fausto, & G E Sonenshein. (1997). Nuclear factor-kappaB/Rel blocks transforming growth factor beta1-induced apoptosis of murine hepatocyte cell lines.. PubMed. 8(10). 1049–59.90 indexed citations
8.
Bellas, Robert E., Mark J. Fitzgerald, N Fausto, & G E Sonenshein. (1997). Inhibition of NF-kappa B activity induces apoptosis in murine hepatocytes.. PubMed. 151(4). 891–6.138 indexed citations
Kessler, D. J., et al.. (1992). A novel NF-kappa B element within exon 1 of the murine c-myc gene.. PubMed. 7(12). 2447–53.27 indexed citations
13.
Maheswaran, Shyamala, James E. McCormack, & G E Sonenshein. (1991). Changes in phosphorylation of myc oncogene and RB antioncogene protein products during growth arrest of the murine lymphoma WEHI 231 cell line.. PubMed. 6(11). 1965–71.29 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.